

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: April 21, 2004

Kimberly J. Prior

(Print Name)

(Signature)

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Group: 1614

Synese Jolidon, et al.

Serial No.: 10/625,116

Filed: July 22, 2003

For: **2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES**

TRANSMITTAL OF CERTIFIED COPY

April 21, 2004


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Attached please find the certified copy of the foreign application from which priority is claimed for this case:

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>
Europe	02017676.4	August 7, 2002

Respectfully submitted,


Kimberly J. Prior
Attorney for Applicant

Reg. No. 41,483
Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley, New Jersey 07110
Phone: (973) 235-6208

KJP/bah
Enclosures

THIS PAGE BLANK (USPTO)



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

•

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02017676.4

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

THIS PAGE BLANK (USPTO)



Anmeldung Nr:
Application no.: 02017676.4
Demande no:

Anmeldetag:
Date of filing: 07.08.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

F. HOFFMANN-LA ROCHE AG

4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

2,3-Dihydro-isoinol-1-one derivatives as MAO-B inhibitors

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07D471/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

THIS PAGE BLANK (USPTO)

X is $-N=$ or $-CH=$;

$$-(\text{CH}_2)_n-\text{NR}^5\text{R}^6,$$
$$-(\text{CH}_2)_n-\text{COOR}^7;$$
$$-(\text{CH}_2)_n-\text{CN};$$

-(CH₂)_n-isoindole-1,3-dionyl; or

$$-(\text{CH}_2)_p-\text{OR}^8;$$

R^2 is hydrogen or C_1 - C_6 -alkyl;

R^3 is hydrogen or C_1 - C_6 -alkyl;

15 R⁴ is halogen, halogen-(C₁-C₆)-alkyl, C₁-C₆-alkoxy or
halogen-(C₁-C₆)-alkoxy;

R⁵ and R⁶ are independently from each other hydrogen or C₁-C₃-alkyl;

R⁷ is C₁-C₆-alkyl;

R⁸ is hydrogen or C₁-C₆-alkyl;

m is 1, 2 or 3;

n is 0, 1 or 2; and

p is 1 or 2;

5 as well as their pharmaceutically acceptable salts.

It has been found that the compounds of general formula I or II are selective monoamine oxidase B inhibitors.

Monoamine oxidase (MAO, EC 1.4.3.4) is a flavin-containing enzyme responsible for the oxidative deamination of endogenous monoamine neurotransmitters such as
10 dopamine, serotonin, adrenaline, or noradrenaline, and trace amines, e.g. phenylethylamine, as well as a number of amine xenobiotics. The enzyme exists in two forms, MAO-A and MAO-B, encoded by different genes (A. W. Bach et al., *Proc. Natl. Acad. Sci. USA* 1988, 85, 4934-4938) and differing in tissue distribution, structure and substrate specificity. MAO-A has higher affinity for serotonin, octopamine, adrenaline, and
15 noradrenaline; whereas the natural substrates for MAO-B are phenylethylamine and tyramine. Dopamine is thought to be oxidised by both isoforms. MAO-B is widely distributed in several organs including brain (A.M. Cesura and A. Pletscher, *Prog. Drug Research* 1992, 38, 171-297). Brain MAO-B activity appears to increase with age. This increase has been attributed to the gliosis associated with aging (C.J. Fowler et al., *J.*
20 *Neural. Transm.* 1980, 49, 1-20). Additionally, MAO-B activity is significantly higher in the brains of patients with Alzheimer's disease (P. Dostert et al., *Biochem. Pharmacol.* 1989, 38, 555-561) and it has been found to be highly expressed in astrocytes around senile plaques (Saura et al., *Neuroscience* 1994, 70, 755-774). In this context, since oxidative deamination of primary monoamines by MAO produces NH₃, aldehydes and H₂O₂, agents with
25 established or potential toxicity, it is suggested that there is a rationale for the use of selective MAO-B inhibitors for the treatment of dementia and Parkinson's disease. Inhibition of MAO-B causes a reduction in the enzymatic inactivation of dopamine and thus prolongation of the availability of the neurotransmitter in dopaminergic neurons. The degeneration processes associated with age and Alzheimer's and Parkinson's diseases
30 may also be attributed to oxidative stress due to increased MAO activity and consequent increased formation of H₂O₂ by MAO-B. Therefore, MAO-B inhibitors may act by both reducing the formation of oxygen radicals and elevating the levels of monoamines in the brain.

Given the implication of MAO-B in the neurological disorders mentioned above,
35 there is considerable interest to obtain potent and selective inhibitors that would permit control over this enzymatic activity. The pharmacology of some known MAO-B inhibitors

is for example discussed by D. Bentué-Ferrer et al. in *CNS Drugs* 1996, 6, 217-236.

Whereas a major limitation of irreversible and non-selective MAO inhibitor activity is the need to observe dietary precautions due to the risk of inducing a hypertensive crisis when dietary tyramine is ingested, as well as the potential for interactions with other medications
5 (D. M. Gardner et al., *J. Clin. Psychiatry* 1996, 57, 99-104), these adverse events are of less concern with reversible and selective MAO inhibitors, in particular of MAO-B. Thus, there is a need for MAO-B inhibitors with a high selectivity and without the adverse side-effects typical of irreversible MAO inhibitors with low selectivity for the enzyme.

Object of the present invention therefore is to provide compounds which must have
10 the criteria mentioned above. It has been found that the compounds of formula I or formula II of the present invention show the potential to be highly selective MAO-B inhibitors. Subjects of the present invention are further a process for the manufacture of compounds of formula I or formula II as well as the use of the compounds of formula I or formula II in the control or prevention of diseases mediated by monoamine oxidase B
15 inhibitors, and, respectively, their use for the production of corresponding medicaments.

The following definitions of general terms used in the present patent application apply irrespective of whether the terms in question appear alone or in combination. It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an," and "the" include plural forms unless the context clearly dictates otherwise.

20 The term "C₁-C₆-alkyl" ("lower alkyl") used in the present application denotes straight-chain or branched saturated hydrocarbon residues with 1 to 6 carbon atoms, preferably with 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, t-butyl, and the like.

The term "halogen" denotes fluorine, chlorine, bromine and iodine.

25 "Halogen-(C₁-C₆)-alkyl" means the lower alkyl residue as defined herein substituted in any position with one or more halogen atoms as defined herein. Examples of halogenalkyl residues include, but are not limited to, 1,2-difluoropropyl, 1,2-dichloropropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, and 1,1,1-trifluoropropyl, and the like.

30 "C₁-C₆-Alkoxy" means the residue -O-R, wherein R is a lower alkyl residue as defined herein. Examples of alkoxy radicals include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like.

"Pharmaceutically acceptable salts" of a compound means salts that are pharmaceutically acceptable, which are generally safe, non-toxic, and neither biologically

nor otherwise undesirable, and that possess the desired pharmacological activity of the parent compound. These salts are derived from an inorganic or organic acid or base.

Such salts include:


- (1) acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, dibenzoyl-L-tartaric acid, tartaric acid, p-toluene-sulfonic acid, trimethylacetic acid, 2,2,2-trifluoroacetic acid, and the like; or
- (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic or inorganic base. Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.

It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) of the same acid addition salt.

Among compounds of the present invention certain compounds of formula I or II, or pharmaceutically acceptable salts thereof, are preferred.

Preferred compounds of formula I or II are those, in which X is $-\text{CH}=\text{}$.

Especially preferred are compounds of the general formula



wherein

X is $-\text{N}=\text{}$ or $-\text{CH}=\text{}$;

- R^1 is $-(CH_2)_n-CO-NR^5R^6$;
 $-(CH_2)_n-NR^5R^6$;
 $-(CH_2)_n-COOR^7$;
 $-(CH_2)_n-CN$;
5 $-(CH_2)_n$ -isoindole-1,3-dionyl; or
 $-(CH_2)_p-OR^8$;
- R^2 is hydrogen or C_1-C_6 -alkyl;
 R^3 is hydrogen or C_1-C_6 -alkyl;
 R^4 is halogen, halogen- (C_1-C_6) -alkyl, C_1-C_6 -alkoxy or
10 halogen- (C_1-C_6) -alkoxy;
- R^5 and R^6 are independently from each other hydrogen or C_1-C_3 -alkyl;
 R^7 is C_1-C_6 -alkyl;
 R^8 is hydrogen or C_1-C_6 -alkyl;
m is 1, 2 or 3;
15 n is 0, 1 or 2; and
p is 1 or 2;

as well as their pharmaceutically acceptable salts.

Preferred compounds of formula I are those, wherein R^1 is $-(CH_2)_n-CO-NR^5R^6$, and
wherein R^5 and R^6 are independently from each other hydrogen or C_1-C_6 -alkyl and n is 0, 1
20 or 2.


The following compounds are examples thereof:

- 2-[5-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide,
2-[5-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
(S)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
25 (R)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
2-[5-(4-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide, and
2-[1-oxo-5-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetamide.

Another group of preferred compounds of formula I are those, wherein R^1 is $-(CH_2)_p-OR^8$, and wherein R^8 is C_1-C_6 -alkyl and n is 0, 1, or 2.

- 30 5-(3-Fluoro-benzyloxy)-2-(2-methoxy-ethyl)-2,3-dihydro-isoindol-1-one is an example of such a compound.

Also preferred are compounds of the general formula



wherein

- X is -N= or -CH=;
- 5 R¹ is -(CH₂)_n-CO-NR⁵R⁶;
 -(CH₂)_n-NR⁵R⁶;
 -(CH₂)_n-COOR⁷;
 -(CH₂)_n-CN;
 -(CH₂)_n-isoindole-1,3-dionyl; or
 10 -(CH₂)_p-OR⁸;
- R² is hydrogen or C₁-C₆-alkyl;
- R³ is hydrogen or C₁-C₆-alkyl;
- R⁴ is halogen, halogen-(C₁-C₆)-alkyl, C₁-C₆-alkoxy or
 halogen-(C₁-C₆)-alkoxy;
- 15 R⁵ and R⁶ are independently from each other hydrogen or C₁-C₃-alkyl;
- R⁷ is C₁-C₆-alkyl;
- R⁸ is hydrogen or C₁-C₆-alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2; and
- 20 p is 1 or 2;

as well as their pharmaceutically acceptable salts.

Especially preferred compounds of formula II are those, wherein R¹ is -(CH₂)_n-CO-NR⁵R⁶, and wherein R⁵ and R⁶ are independently from each other hydrogen or C₁-C₆-alkyl and n is 0, 1 or 2.

25 Examples of such compounds are the following:

- 2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide,
- (R)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
- (S)-2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide,

and

(R)-2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide.

Furthermore, compounds of formula II, wherein R^1 is $-(CH_2)_n-COOR^7$, and wherein R^7 is C_1-C_6 -alkyl and n is 0, 1, or 2, are also preferred.

5 The following compounds are examples thereof:

[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester, and
[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester.

10 Further preferred compounds of formula II are those, wherein R^1 is $-(CH_2)_p-OR^8$, and wherein R^8 is C_1-C_6 -alkyl and p is 1 or 2.

2-(2-Methoxy-ethyl)-6-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one, and
2-(2-methoxy-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one are examples thereof.

15 Also preferred are compounds of formula II, wherein R^1 is $-(CH_2)_n-NR^5R^6$, and wherein R^5 and R^6 are independently from each other hydrogen or C_1-C_6 -alkyl and n is 0, 1 or 2.


The following compounds are examples thereof:

2-(2-amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride, and
20 2-(2-amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride.

The compounds of formula I or formula II are substituted by one, two or three R^4 selected from the group consisting of C_1-C_3 -alkyl, halogen, halogen- (C_1-C_6) -alkyl, C_1-C_6 -alkoxy or halogen- (C_1-C_6) -alkoxy, preferably they are substituted by one R^4 .


25 Especially preferred compounds of formula I or formula II are those, wherein R^4 is halogen or halogen- (C_1-C_6) -alkyl. Especially preferred are those compounds of formula I, wherein R^4 is fluoro or trifluoromethyl.

The compounds of general formula I or formula II and their pharmaceutically acceptable salts can be manufactured by reacting a compound of formula




III

with a compound of formula



IV


to obtain a compound of formula



I


and, if desired, converting a compound of formula I into a pharmaceutically acceptable salt, or

by reacting a compound of formula




V

10 with a compound of formula



IV


to obtain a compound of formula



II


and, if desired, converting a compound of formula II into a pharmaceutically acceptable salt, or

5 by reacting a compound of formula




VI

which is then treated with a compound of formula



VII

to obtain a compound of formula




IIa

10 and, if desired, converting a compound of formula IIa into a pharmaceutically acceptable salt.

In accordance with the present invention, compounds of general formula I can be prepared following schemes 1 and 2: A compound of formula VIII is heated in presence of
15 methanol and an acid such as hydrochloric acid. The obtained compound IX is then brominated by the use of N-bromosuccinimide to give X which in turn in a one-pot


process is transformed to a compound of formula XI via treatment with sodium azide, reduction of the obtained compound XII with triphenylphosphine in the presence of water and cyclisation by heating in the presence of methanol. Treatment of a compound of formula XII with boron tribromide in dichloromethane affords compounds of formula XIII.

Scheme 1



Compounds of general formula I can be prepared following scheme 2: A compound of formula I can be obtained by treating compounds of type IIIa or III which are dissolved in THF and treated with sodium hydride and an electrophile of formula IV.


Scheme 2



In accordance with the present invention, compounds of general formula II can be prepared following schemes 3 and 4: Starting from the para-fluoro anisole or the 4-fluoro-3-methylanisole the acid XIV can be formed by ortho-metallation and quenching with carbon monoxide or by oxidation with KMnO₄ respectively. The product can then be transformed into the acid chloride and treated with the amine XV in dichloromethane with sodium carbonate as base. The resulting amide XVI can then be cyclised to XVII using potassium bis(trimethylsilyl)amide (KHMDs) or by treatment with 2,2,6,6-


tetramethylpiperidine and n-Butyl lithium (BuLi) in THF as solvent. Treatment of XVII with aqueous sodium hydroxide affords the compound XVIII which can then be transformed into the amide XIX by treatment with a mixture of ammonium cerium nitrate (CAN) in acetonitrile water or by treatment with trifluoroacetic acid (TFA) in dichloromethane. Further reaction at low temperature with BBr₃ in dichloromethane affords the compound XX which can be elaborated to the desired products II as described above.

Scheme 3



Alternatively, starting from 4-hydroxyphthalic acid XXI treatment with excess of XXII in the presence of a base such as potassium carbonate in a solution of water : THF gives the product XXIII which can be isolated and then reduced with LiAlH₄ in diethyl ether to afford XXIV. Oxidation using Swern conditions in dichloromethane provides access to the dialdehyde VI which can be treated with the amines VII to afford the desired products IIa or Ia by addition or exclusion of triethylamine.

Scheme 4



Pharmaceutically acceptable salts of compounds of formula I or II can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt. Inorganic or organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I or II.

Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation of pharmaceutically acceptable salts of acidic compounds.

The compounds of formula I or II and their pharmaceutically acceptable salts are, as already mentioned above, monoamine oxidase B inhibitors and can be used for the treatment or prevention of diseases in which MAO-B inhibitors might be beneficial. These include acute and chronic neurological disorders, cognitive disorders and memory deficits. Treatable neurological disorders are for instance traumatic or chronic degenerative processes of the nervous system, such as Alzheimer's disease, other types of dementia, minimal cognitive impairment or Parkinson's disease. Other indications include psychiatric diseases such as depression, anxiety, panic attack, social phobia, schizophrenia, eating and metabolic disorders such as obesity as well as the prevention and treatment of withdrawal syndromes induced by abuse of alcohol, nicotine and other addictive drugs. Other treatable indications may be reward deficiency syndrome (G.M. Sullivan,

International patent application No. WO 01/34172 A2), peripheral neuropathy caused by cancer chemotherapy (G. Bobotas, International Patent Application No. WO 97/33572 A1), or the treatment of multiple sclerosis (R.Y. Harris, International patent application No. WO 96/40095 A1) and other neuroinflammatory diseases.

- 5 The compounds of formula I or II and their pharmaceutically acceptable salts are especially useful for the treatment and prevention of Alzheimer's disease and senile dementia.

 The pharmacological activity of the compounds was tested using the following method:

- 10 The cDNA's encoding human MAO-A and MAO-B were transiently transfected into EBNA cells using the procedure described by E.-J. Schlaeger and K. Christensen (Transient Gene Expression in Mammalian Cells Grown in Serum-free Suspension Culture; Cytotechnology, 15: 1-13, 1998). After transfection, cells were homogenized by means of a Polytron homogenizer in 20 mM Tris HCl buffer, pH 8.0, containing 0.5 mM EGTA and
15 0.5 mM phenylmethanesulfonyl fluoride. Cell membranes were obtained by centrifugation at 45,000 x g and, after two rinsing step with 20 mM Tris HCl buffer, pH 8.0, containing 0.5 mM EGTA, membranes were eventually re-suspended in the above buffer and aliquots stored at -80 °C until use.

- MAO-A and MAO-B enzymatic activity was assayed in 96-well-plates using a
20 spectrophotometric assay adapted from the method described by M. Zhou and N. Panchuk-Voloshina (A One-Step Fluorometric Method for the Continuous Measurement of Monoamine Oxidase Activity, Analytical Biochemistry, 253: 169-174, 1997). Briefly, membrane aliquots were incubated in 0.1 M potassium phosphate buffer, pH 7.4, for 30 min at 37 °C with or without various concentrations of the compounds. After this period,
25 the enzymatic reaction was started by the addition of the MAO substrate tyramine together with 1 U/ml horse-radish peroxidase (Roche Biochemicals) and 80 µM N-acetyl-3,7,-dihydroxyphenoxazine (Amplex Red, Molecular Probes). The samples were further incubated for 30 min at 37 °C in a final volume of 200 µl and absorbance was then determined at a wavelength of 570 nm using a SpectraMax plate reader (Molecular
30 Devices). Background (non-specific) absorbance was determined in the presence of 10 µM clorgyline for MAO-A or 10 µM L-deprenyl for MAO-B.

 IC₅₀ values were determined from inhibition curves obtained using nine inhibitor concentrations in duplicate, by fitting data to a four parameter logistic equation using a computer program.

The compounds of the present invention are specific MAO-B inhibitors. The activities of compounds of formula I or II as measured in the assay described above are in the range of 10 μ M or less, typically of 1 μ M or less, and ideally 0.03 μ M or less.

5 The compounds of formula I or II and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

10 The compounds of formula I or II and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, 15 for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for 20 aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying 25 the osmotic pressure, buffers, masking agents or antioxidants. They may also contain other therapeutically valuable substances.

As mentioned earlier, medicaments containing a compound of formula I or II or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments 30 which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.

The dosage can vary within wide limits and will, of course, be fitted to the individual 35 requirements in each particular case. In general, the effective dosage for oral or parenteral

administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day.

- 5 The following examples are provided for illustration of the invention. They should not be considered as limiting the scope of the invention, but merely as being representative thereof.

Example 1

2-[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

10 a) 4-Methoxy-2-methyl-benzoic acid methyl ester

According to *J. Org. Chem.* 1968, 33, 494, a mixture of 4-methoxy-2-methylbenzoic acid (20 g, 120 mmol) and MeOH (97 mL) containing sulfuric acid (conc., 0.6 mL) was heated under reflux 48 h. After cooling the mixture was evaporated and the residue diluted with diethyl ether and washed with a saturated sodium hydrogen carbonate solution and brine.

- 15 The organic phase was then separated and dried over sodium sulphate. After evaporation the residue was distilled through a 8 cm Vigreux column to afford the title compound (21.2 g, 98%) as a colourless liquid. Bp 60 °C / 1 mbar. MS: m/e = 180.3 (M⁺).

b) 2-Bromomethyl-4-methoxy-benzoic acid methyl ester

- A mixture of 4-methoxy-2-methyl-benzoic acid methyl ester (20 g, 111 mmol), N-
20 bromosuccinimide (20.7 g, 117 mmol) and dibenzoylperoxide (0.54 g, 2 mmol) in CCl₄ (150 mL) was irradiated with a 300 W lamp. The reaction maintains a steady reflux and after 4.5 h, the lamp was removed and the mixture cooled to 5 °C. The mixture was then filtered, the filtrate evaporated and the residue purified twice by chromatography (SiO₂, Heptane: Diethyl ether: 95:5 to 85:15) to afford the title product (16.6 g, 58%) as a white
25 solid. MS m/e = 258.1 (M-H⁺).

c) 5-Methoxy-2,3-dihydro-isoindol-1-one

- A mixture of 2-bromomethyl-4-methoxy-benzoic acid methyl ester (7.0 g, 27 mmol) and sodium azide (2.3 g, 35 mmol) in DMF (100 mL) was heated at 50 °C for 16 h. After cooling to room temperature the mixture was diluted with water (100 mL) and the
30 mixture extracted with diethyl ether (3 x 100 mL). The combined organic phases were then washed with brine, dried over sodium sulfate. Filtration and evaporation afforded the azido product as a clear oil which was then dissolved in THF (100 mL) and then triphenylphosphine (7.1 g, 27 mmol) added followed by water (0.7 mL, 41 mmol) and the

resulting mixture stirred at room temperature for 24 h and then heated at 55 °C for 48 h. Then MeOH (2 mL) was added and the mixture heated at 70 °C for 3 h. After cooling to room temperature, the mixture was evaporated and the residue purified by chromatography (SiO₂, CH₂Cl₂: 2N NH₃-MeOH 99:1 to 94:6) to afford the title product (3.8 g, 86%)
5 as an off-white solid. MS m/e = 163.3 (M⁺).

d) 5-Hydroxy-2,3-dihydro-isoindol-1-one

A mixture of 5-methoxy-2,3-dihydro-isoindol-1-one (3.7 g, 23 mmol) and boron tribromide (1 M in CH₂Cl₂, 15.2 mL, 88 mmol) in CH₂Cl₂ (30 mL) at -78 °C was stirred for 16 h at room temperature. The mixture was then cooled to -78 °C and MeOH (25 mL)
10 was added. After 1 h at -78 °C the mixture was evaporated and the residue purified by chromatography (SiO₂, CH₂Cl₂: 2N NH₃-MeOH 98:2 to 90:10) to afford the title product (2.5 g, 72%) as an off-white solid. MS m/e = 148.0 (M-H⁺).

e) 5-(3-Fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one

A mixture of 5-hydroxy-2,3-dihydro-isoindol-1-one (2.4 g, 16 mmol), potassium
15 carbonate (2.4 g, 18 mmol) and 3-fluorobenzyl bromide (3.3 g, 18 mmol) in acetone (40 mL) was heated under reflux for 22 h. After cooling to room temperature the mixture was filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂: 2N NH₃-MeOH 90:10) to afford the title product (2.8 g, 67%) as a white solid. MS m/e = 257.2 (M⁺).

20 f) 2-[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

A mixture of 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (400 mg, 1.6 mmol), sodium hydride (55% in mineral oil, 75 mg, 1.7 mmol) in THF (20 mL) was stirred at rt for 45 min, and then 2-bromoacetamide (75 mg, 1.9 mmol) was added and the resulting mixture heated at 50 °C for 16 h. After cooling to room temperature the mixture was half-
25 evaporated and diluted with water. The mixture was extracted with ethyl acetate and the combined organic layers were washed with brine and dried over sodium sulfate. After filtration and evaporation the residue was purified by chromatography (SiO₂, CH₂Cl₂: 2N NH₃-MeOH 98:2 to 85:15) to afford the title product (337 mg, 67%) as a white solid. MS m/e = 315.3 (M+H⁺).

Example 2

2-[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide

As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (250 mg, 0.97 mmol) was converted to the title compound (58 mg, 18%) (using 2-bromopropion-
amide instead of 2-bromoacetamide) which was obtained as a white solid. MS m/e = 329.3 (M+H⁺).

Example 3

(S)-2-[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide

a) 4-(3-Fluoro-benzyloxy)-phthalic acid bis-(3-fluoro-benzyl) ester

A mixture of 4-hydroxyphthalic acid (5.0 g, 27.5 mmol), 3-fluorobenzylbromide (31.14 g, 164.7 mmol) and potassium carbonate (15.18 g, 109.8 mmol) in THF : water (1 : 1, 200 mL) was heated under reflux for 72 h. After cooling to room temperature, the mixture was then half evaporated and the residue extracted with ethyl acetate (100 mL). The organic layer was then washed with brine, dried over sodium sulfate, filtered and evaporated. The mixture was then heated in a Kugelrohr apparatus (160 °C at 15 mmHg) to remove the excess 3-fluorobenzylbromide to leave the title compound (13.1 g, 94%) as a light yellow liquid. MS m/e = 506.1 (M).

b) [5-(3-Fluoro-benzyloxy)-2-hydroxymethyl-phenyl]-methanol

To a suspension of lithium aluminium hydride (2.15 g, 56.9 mmol) and diethyl ether (150 mL) at 0 °C was added a solution of 4-(3-fluoro-benzyloxy)-phthalic acid bis-(3-fluoro-benzyl) ester (13.1 g, 25.9 mmol) in diethyl ether (150 mL) over 1 h. After a further 1.5 h water (100 mL) and sulfuric acid (2M, 100 mL) was added and the resulting mixture was extracted with diethyl ether (2 x 100 mL). The combined extracts were then dried over sodium sulfate, filtered and evaporated to leave a clear oil which was purified by chromatography (SiO₂, hexane: ethyl acetate 1 : 1 to 2 : 3) to afford the title product (5.1 g, 76%) as a white solid. MS m/e = 260.6 (M+H⁺).

c) 4-(3-Fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde

To a cooled solution of oxalyl chloride (13.3 g, 104.8 mmol) in dichloromethane (150 mL) at -78 °C was added a solution of DMSO (16.4 g, 209.7 mmol) in dichloromethane (35 mL) followed by the addition of a solution of 5-(3-fluoro-benzyloxy)-2-hydroxymethyl-phenyl]-methanol (5.1 g, 19.6 mmol) in DMSO : dichloromethane (1 : 3, 20 mL).

Triethylamine (85.8 g, 848.3 mmol) was then added dropwise to this solution over 30 min, and the resulting reaction mixture was allowed to warm up to room temperature over 72 h. Then water (300 mL) was added and the product extracted with dichloromethane (2 x 300 mL). The combined extracts were then dried over sodium sulfate, filtered and
5 evaporated to leave a clear oil which was purified by chromatography (SiO₂, hexane: ethyl acetate 3 : 2) to afford the title product (4.0 g, 79%) as a light brown solid. MS m/e = 258.1 (M⁺).

d) (S)-2-[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide

To a cooled (0 °C) solution of 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (271.0
10 mg, 1.05 mmol) in dichloromethane (5 mL) was added H-Ala-NH₂ HCl (184.9 mg, 2.10 mmol) and the resulting mixture was warmed up to room temperature over 1 h and then heated at 50 °C for 1 h. After cooling to room temperature, the mixture was evaporated and the residue partitioned between ethyl acetate and hydrochloric acid (1 N). The organic layer was then dried over sodium sulfate, filtered and evaporated to leave a clear oil which
15 was purified by chromatography (SiO₂, dichloromethane : MeOH 9 : 1) to afford the title product (87 mg, 25%) as a light brown solid. MS m/e = 329.2 (M+H⁺).

Example 4

(R)-2-[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide

As described for example 3d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0
20 mg, 0.97 mmol) was converted to the title compound (62.5 mg, 20%) (using H-D-Ala-NH₂ HCl instead of H-Ala-NH₂ HCl) which was obtained as a light brown solid. MS m/e = 327.5 (M-H⁻).

Example 5

3-[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide

25 As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (250 mg, 0.97 mmol) was converted to the title compound (166 mg, 52%) (using 3-bromopropionamide instead of 2-bromoacetamide) which was obtained as a white solid. MS m/e = 329.3 (M+H⁺).

Example 6

[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetic acid ethyl ester

As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (250 mg, 0.97 mmol) was converted to the title compound (242 mg, 73%) (using ethyl bromo acetate instead of 2-bromoacetamide) which was obtained as a light-yellow solid. MS = m/e 344.3 (M+H⁺).

Example 7

[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester

As described for example 3d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.97 mmol) was converted to the title compound (71 mg, 22%) (using glycine methylester HCl instead of H-Ala-NH₂ HCl) which was obtained as a light brown solid. MS m/e = 330.2 (M-H⁺).

Example 8

2-[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionic acid ethyl ester

As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (250 mg, 0.97 mmol) was converted to the title compound (119 mg, 34%) (using ethyl 2-bromopropionate instead of 2-bromoacetamide) which was obtained as a light-yellow solid. MS m/e = 358.3 (M+H⁺).

Example 9

[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetic acid tert-butyl ester

As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (250 mg, 0.97 mmol) was converted to the title compound (187 mg, 52%) (using tert-butyl bromoacetate instead of 2-bromoacetamide) which was obtained as a light-yellow solid. MS m/e = 372.3 (M+H⁺).

Example 10

[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-hydroxy-acetic acid ethyl ester

As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (250 mg, 0.97 mmol) was converted to the title compound (8 mg, 2%) (using ethyl bromofluoroacetate instead of 2-bromoacetamide) which was obtained as a light-yellow solid. MS m/e = 360.3 (M+H⁺).

Example 11

5-(3-Fluoro-benzyloxy)-2-(2-methoxy-ethyl)-2,3-dihydro-isoindol-1-one

As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (150 mg, 0.58 mmol) was converted to the title compound (33 mg, 18%) (using 2-bromoethyl methylether instead of 2-bromoacetamide) which was obtained as an off-white solid. MS m/e = 315.2 (M⁺).

Example 12

2-{3-[5-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propyl}-isoindole-1,3-dione

As described for example 1f, 5-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (250 mg, 0.97 mmol) was converted to the title compound (35 mg, 8%) (using N-(3-bromopropyl)-phthalimide instead of 2-bromoacetamide) which was obtained as a yellow solid. MS m/e = 445.4 (M⁺).

Example 13

5-(3-Fluoro-benzyloxy)-2-(2-hydroxy-ethyl)-2,3-dihydro-isoindol-1-one

a) 5-Methoxy-2-(2-methoxy-ethyl)-2,3-dihydro-isoindol-1-one

A mixture of 2-bromomethyl-4-methoxy-benzoic acid methyl ester (1.0 g, 3.9 mmol), triethylamine (391 mg, 3.9 mmol) and 2-methoxy-ethylamine (348 mg, 4.6 mmol) was heated under reflux for 2 h. After cooling to room temperature the mixture was filtered and evaporated. The residue was purified by chromatography (SiO₂, Heptane: EtOAc 1:1 to EtOAc) to afford the title product (260 mg, 30%) as a light yellow solid. MS m/e = 221.3 (M⁺).

b) 5-Hydroxy-2-(2-hydroxy-ethyl)-2,3-dihydro-isoindol-1-one

A mixture of 5-methoxy-2-(2-methoxy-ethyl)-2,3-dihydro-isoindol-1-one (150 mg, 0.68 mmol) and boron tribromide (1 M in CH₂Cl₂, 1.4 mL, 1.36 mmol) in CH₂Cl₂ (8 mL) at -78 °C was stirred for 16 h at room temperature. The mixture was then cooled to -78 °C and MeOH (25 mL) was added. After 1 h at -78 °C the mixture was evaporated and the residue purified by chromatography (SiO₂, CH₂Cl₂: 2N NH₃-MeOH 98:2 to 90:10) to afford the title product (42 mg, 32%) as a light orange solid. MS m/e = 193.3 (M⁺).

c) 5-(3-Fluoro-benzyloxy)-2-(2-hydroxy-ethyl)-2,3-dihydro-isoindol-1-one

As described for example 1e, 5-(3-fluoro-benzyloxy)-2-(2-hydroxy-ethyl)-2,3-dihydro-isoindol-1-one (30 mg, 0.16 mmol) was converted to the title compound (11 mg, 24%) which was obtained as a white solid. MS m/e = 301.1 (M⁺).

Example 14

2-[5-(4-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

a) 5-(4-Fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one

As described for example 1e, 5-hydroxy-2,3-dihydro-isoindol-1-one (190 mg, 1.28 mmol) was converted to the title compound (236 mg, 72%) (using 4-fluoromethylbenzyl bromide instead of 3-fluorobenzyl bromide) which was obtained as a white solid. MS m/e = 257.9 (M+H⁺).

b) 2-[5-(4-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

As described for example 1f, 5-(4-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (200 mg, 0.65 mmol) was converted to the title compound (127 mg, 52%) which was obtained as a white solid. MS m/e = 315.2 (M+H⁺).

Example 15

2-[1-Oxo-5-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetamide

a) 5-(4-Trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one

As described for example 1e, 5-hydroxy-2,3-dihydro-isoindol-1-one (190 mg, 1.28 mmol) was converted to the title compound (287 mg, 73%) (using 4-trifluoromethylbenzyl bromide instead of 3-fluorobenzyl bromide) which was obtained as a white solid. MS m/e = 308.1 (M+H⁺).

b) 2-[1-Oxo-5-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetamide

As described for example 1f, 5-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one (200 mg, 0.78 mmol) was converted to the title compound (133 mg, 47%) which was obtained as a white solid. MS m/e = 365.2 (M+H⁺).

5

Example 16

[1-Oxo-5-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetonitrile

a) 4-(4-Trifluoromethyl-benzyloxy)-phthalic acid bis-(4-trifluoromethyl-benzyl) ester

As described for example 3a, 4-hydroxyphthalic acid (5.0 g, 27.5 mmol) was converted to the title compound (12.5 mg, 69%) (using 4-(trifluoromethyl)-benzylbromide instead of
10 3-fluorobenzylbromide) which was obtained as a white solid. MS m/e = 674.2 (M+H₂O⁺).

b) [2-Hydroxymethyl-5-(4-trifluoromethyl-benzyloxy)-phenyl]-methanol

As described for example 3b, 4-(4-trifluoromethyl-benzyloxy)-phthalic acid bis-(4-trifluoromethyl-benzyl) ester (12.5 g, 19.0 mmol) was converted to the title compound (4.8 g, 80%) which was obtained as a white solid. MS m/e = 331.0 (M-H⁻).

15 c) 4-(4-Trifluoromethyl-benzyloxy)-benzene-1,2-dicarbaldehyde

As described for example 3c, [2-hydroxymethyl-5-(4-trifluoromethyl-benzyloxy)-phenyl]-methanol (4.75 g, 15.2 mmol) was converted to the title compound (3.95 g, 84%) which was obtained as a light yellow solid. MS m/e 308.1 (M⁺)

d) [1-Oxo-5-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetonitrile

20 To a cooled (0 °C) solution of 4-(4-trifluoromethyl-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.81 mmol) in DMF (7 mL) was added aminoacetonitrile HCl (150.1 mg, 1.62 mmol) and triethylamine (164.1 mg, 1.62 mmol) and the resulting mixture was warmed up to room temperature over 1 h and then heated at 50 °C for 1 h. After cooling to room temperature, the mixture was evaporated and the residue partitioned
25 between ethyl acetate and hydrochloric acid (1 N). The organic layer was then dried over sodium sulfate, filtered and evaporated to leave a clear oil which was purified by chromatography (SiO₂, DCM : MeOH 9 : 1) to afford the title product (19.6 mg, 7%) as a light brown solid. MS m/e = 345.2 (M-H⁻).

Example 17

2-[5-(3,5-Bis-trifluoromethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

a) 5-(3,5-Bis-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one

As described for example 1e, 5-hydroxy-2,3-dihydro-isoindol-1-one (170 mg, 1.13 mmol) was converted to the title compound (305 mg, 71%) (using 3,5- bis(trifluoromethyl)benzyl bromide instead of 3-fluorobenzyl bromide) which was obtained as a white solid. MS m/e = 376.2 (M+H⁺).

b) 2-[5-(3,5-Bis-trifluoromethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

As described for example 1f, 5-(3,5-bis-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one (200 mg, 0.53 mmol) was converted to the title compound (118 mg, 51%) which was obtained as a white solid. MS m/e = 433.2 (M+H⁺).

Example 18

2-[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

a) 2-Fluoro-5-methoxy-benzoic acid

To a vigorously stirred mixture of 4-fluoro-3-methylanisole (12.0 g, 85.6 mmol) and pyridine (41.7 g, 527 mmol) in water (170 mL) at 50 °C was added portion-wise potassium permanganate (44.65 g, mmol) and then maintained at this temperature for 2 h. The resulting mixture was then allowed to cool to room temperature and allowed to stand overnight and then heated for a further 5 h at 50 °C. Then the mixture was filtered over celite and then the residue was washed with sulfuric acid (conc. 100mL). The combined filtrates were then half-evaporated and neutralised with potassium carbonate. Then the mixture was washed with diethyl ether and then the aqueous layer was acidified with hydrochloric acid (conc.) and the product extracted with diethyl ether. The combined extracts were then dried over sodium sulphate. After filtration and evaporation the crude solid was recrystallised from 1,2-dichloroethane to afford the title compound (4.4 g, 30%) as a light pink solid. MS m/e = 168.9 (M-H).

Alternatively, a solution of 4-fluoroanisole (500 mg, 4.0 mmol) in THF (10 mL) was added to a cooled solution (−78 °C) of 2,2,6,6-tetramethylpiperidine (1.1 g, 7.9 mmol) and BuLi (5 mL, 1.6 M in hexanes, 7.9 mmol) in THF (10 mL) at a slow rate to maintain the temperature below −70 °C. The mixture was maintained at this temperature for 12 h, and then dry CO₂ gas was passed into the solution. The resulting mixture was allowed to warm up to 0 °C and then HCl (1 M, 10 mL) was added and the product was extracted with

diethyl ether. The combined organic extracts were then dried over sodium sulfate, washed with water and brine, filtered and evaporated. The crude solid was then partitioned between sodium hydroxide (1 M, 10 mL) and diethyl ether. The aqueous phase was then acidified with HCl (1 M) and the product extracted with diethyl ether. Evaporation afforded the title compound (268 mg, 40%) as a white solid. MS $m/e = 168.9$ (M-H).

b) 2-Fluoro-5-methoxy-benzoyl chloride

A mixture of 2-fluoro-5-methoxy-benzoic acid (4.3 g, 25 mmol) and thionyl chloride (68 mL, 937 mmol) and DMF (1 drop) was stirred at room temperature for 14 hours. The mixture was then evaporated to afford the title compound (4.77 g, 100%) after repeated azeotroping with toluene.

c) 1,3,5-Tris-(4-methoxy-benzyl)-[1,3,5]triazinane

Formaldehyde (8.2 g, 37% in water, 272 mmol) was added to a mixture of 4-methoxy-benzylamine (14.1 g, 103 mmol) in ethanol (10 mL) at 0 °C whereupon a white precipitate formed. The reaction mixture was stirred for 30 minutes at room temperature and then dissolved in ethyl acetate. The organic layer was then washed with water and brine, then dried over sodium sulfate. Filtration and evaporation afforded the title compound (15.5 g, 33%) as a white solid. MS $m/e = 448.3$ (M+H⁺).

d) (Diphenyl-phosphinoylmethyl)-(4-methoxy-benzyl)-amine

To a mixture of 1,3,5-tris-(4-methoxy-benzyl)-[1,3,5]triazinane (8.85 g, 19.8 mmol) in toluene (50 mL) was added diphenylphosphinoxide (4 g, 19.8 mmol) and the resulting mixture heated under reflux for 3 h. After cooling to room temperature the mixture was evaporated. The residue was purified by chromatography (SiO₂, Hexane:Acetone 1:0) to afford the title product (5.7 g, 82%) as a light yellow solid. MS $m/e = 352.3$ (M+H⁺).

e) N-(Diphenyl-phosphinoylmethyl)-2-fluoro-5-methoxy-N-(4-methoxy-benzyl)-benzamide

To a mixture of 2-fluoro-5-methoxy-benzoyl chloride (4.77 g, 25.0 mmol) and sodium carbonate (13.4 g, 126.7 mmol) in dichloromethane (100 mL) cooled to 0 °C was added a solution of (diphenyl-phosphinoylmethyl)-(4-methoxy-benzyl)-amine (8.9 g, 25.3 mmol) in dichloromethane (50 mL) and the resulting mixture allowed to warm up to room temperature overnight. Then the mixture was filtered and evaporated and the residue was purified by chromatography (SiO₂, Hexane:Acetone 1:1) to afford the title product (7.3 g, 57%) as a light yellow solid. MS $m/e = 504.3$ (M+H⁺).

f) 3-(Diphenyl-phosphinoyl)-6-methoxy-2-(4-methoxy-benzyl)-2,3-dihydro-isoindol-1-one

To a cooled solution ($-78\text{ }^{\circ}\text{C}$) of 2,2,6,6-tetramethylpiperidine (5.7 g, 40.3 mmol) in THF (60 mL) was added BuLi (25 mL, 1.6 M in hexanes, 40.3 mmol). To the resulting mixture
5 was added a solution of N-(diphenyl-phosphinoylmethyl)-2-fluoro-5-methoxy-N-(4-methoxy-benzyl)-benzamide (9.2 g, 18.3 mmol) in THF (55 mL) at such a rate to maintain the temperature below $-70\text{ }^{\circ}\text{C}$ and maintained at this temperature for 30 min. The reaction mixture was then allowed to warm up to room temperature over 5 h, and diluted with ammonium chloride (200 mL). The product was then extracted with diethyl ether and the
10 combined extracts washed with brine. The residue was then evaporated and purified by chromatography (SiO_2 , Hexane:Acetone 1:1) to afford the title product (3.6 g, 41%) as a light yellow solid. MS $m/e = 484.3$ ($\text{M}+\text{H}^+$).

g) 6-Methoxy-2-(4-methoxy-benzyl)-2,3-dihydro-isoindol-1-one

A mixture of 3-(diphenyl-phosphinoyl)-6-methoxy-2-(4-methoxy-benzyl)-2,3-dihydro-isoindol-1-one (1.49 g, 3.1 mmol) in THF (40 mL) containing a solution of sodium
15 hydroxide (2.5 M, 12.4 mL, 30.8 mmol) was heated under reflux for 14 h. The solution was then cooled to room temperature and water (40 mL) added. The mixture was extracted with diethyl ether and the combined organic extracts washed with water and brine. The organic layer was then dried over sodium sulphate, filtered and evaporated. The residue
20 was then purified by chromatography (SiO_2 , Hexane:Acetone 6:4) to afford the title product (661 mg, 76%) as a light yellow solid. MS $m/e = 283.2$ (M).

h) 6-Methoxy-2,3-dihydro-isoindol-1-one

A mixture of 6-methoxy-2-(4-methoxy-benzyl)-2,3-dihydro-isoindol-1-one (300 mg, 1.1 mmol) and ammonium ceric nitrate (2.2 g, 4.0 mmol) in acetonitrile : water (12 mL, 2: 1)
25 was stirred at room temperature for 1 h. Then the mixture was poured into water and extracted with ethyl acetate. The combined extracts were then washed with sodium hydrogen carbonate and water. The organic layer was then dried over sodium sulphate, filtered and evaporated. The residue was then purified by chromatography (SiO_2 , dichloromethane : MeOH 20 : 1) to afford the title product (75 mg, 43%) as a light yellow
30 solid. MS $m/e = 164.2$ (M).

Alternatively, a mixture of 6-methoxy-2-(4-methoxy-benzyl)-2,3-dihydro-isoindol-1-one (98.5 mg, 0.35 mmol) in dichloromethane (10 mL) containing TFA (1.6 mL, 20.8 mmol) and TfOH (0.6 mL, 7.0 mmol) was heated overnight at $40\text{ }^{\circ}\text{C}$. Then the mixture was
35 poured into sodium hydrogen carbonate and water and the product extracted with dichloromethane. The combined organic layers were then dried over sodium sulphate,

filtered and evaporated. The residue was then purified by chromatography (SiO₂, dichloromethane : MeOH 20 : 1) to afford the title product (24 mg, 42%) as a light yellow solid. MS m/e = 164.2 (M).

i) 6-Hydroxy-2,3-dihydro-isoindol-1-one

- 5 A mixture of 6-methoxy-2,3-dihydro-isoindol-1-one (167 mg, 1.0 mmol) and boron tribromide (1 M in CH₂Cl₂, 3.6 mL, 3.6 mmol) in CH₂Cl₂ (8 mL) at -78 °C was stirred for 18 h at room temperature. The mixture was then cooled to -78 °C and MeOH (20 mL) was added. After 2 h at -78 °C the mixture was evaporated and the residue purified by chromatography (SiO₂, CH₂Cl₂: 2N NH₃-MeOH 9 : 1) to afford the title product (147 mg, 100%) as a white solid. MS m/e = 148.0 (M-H⁺).

j) 6-(3-Fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one

- 15 A mixture of 6-hydroxy-2,3-dihydro-isoindol-1-one (125.0 mg, 0.84 mmol) and 3-fluorobenzylobromide (174.3 mg, 0.92 mmol) in acetone (5 mL) containing potassium carbonate (276.4 mg, 2.0 mmol) was heated under reflux for 17 h. After cooling to room temperature the mixture was filtered and evaporated. The residue was purified by chromatography (SiO₂, CH₂Cl₂: 2N NH₃-MeOH 90:10) to afford the title product (180 mg, 83%) as a white solid. MS m/e = 258.2 (M+H⁺).

k) 2-[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide

- 20 As described for example 1f, 6-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one (100 mg, 0.39 mmol) was converted to the title compound (110 mg, 90%) which was obtained as a white solid. MS m/e = 315.3 (M+H⁺).

Example 19

(S)-2-[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide

- 25 As described for example 16d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.97 mmol) was converted to the title compound (90.9 mg, 24%) (using H-Ala-NH₂ HCl instead of aminoacetonitrile HCl) which was obtained as a light yellow solid. MS m/e = 329.2 (M+H⁺).

Example 20

(R)-2-[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide

As described for example 16d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.97 mmol) was converted to the title compound (61.9 mg, 20%) (using H-D-Ala-NH₂ HCl instead of aminoacetonitrile HCl) which was obtained as a light yellow solid. MS m/e = 329.3 (M+H⁺).

Example 21

[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester

As described for example 16d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.97 mmol) was converted to the title compound (60.2 mg, 17%) (using glycine methylester HCl instead of aminoacetonitrile HCl) which was obtained as a light brown solid. MS m/e = 330.2 (M+H⁺).

Example 22

2-(2-Methoxy-ethyl)-6-(3-fluoro-benzyloxy)- 2,3-dihydro-isoindol-1-one

As described for example 3d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.97 mmol) was converted to the title compound (35.0 mg, 19%) (using 2-methoxymethylamine instead of H-Ala-NH₂ HCl) which was obtained as a colourless gum. MS m/e = 316.3 (M+H⁺).

Example 23

[6-(3-Fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetonitrile

As described for example 3d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.97 mmol) was converted to the title compound (38.2 mg, 13%) (using aminoacetonitrile HCl instead of H-Ala-NH₂ HCl) which was obtained as a white solid. MS m/e = 297.3 (M+H⁺).

Example 24

2-(2-Amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride

5 a) {2-[1-Oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-ethyl}-carbamic acid tert-butyl ester

As described for example 3d, 4-(3-fluoro-benzyloxy)-benzene-1,2-dicarbaldehyde (250.0 mg, 0.97 mmol) was converted to the title compound (62.5 mg, 16%) (using tert-butyl N-(2-aminoethyl)-carbamate instead of H-Ala-NH₂ HCl) which was obtained as a white solid. MS m/e = 401.4 (M+H⁺).

10 b) 2-(2-Amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride

A mixture of {2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-ethyl}-carbamic acid tert-butyl ester (62.5 mg, 0.16 mmol) and HCl in dioxane (4 N, 5 mL) was stirred at room temperature for 16 h. The precipitate was filtered off and washed
15 with ether to afford the title compound (36.2mg, 69%) as an off-white solid. MS m/e = 301.2 (M+H⁺).

Example 25

(S)-2-[1-Oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide

As described for example 16d, 4-(4-trifluoromethyl-benzyloxy)-benzene-1,2-
20 dicarbaldehyde (250 mg, 0.81 mmol) was converted to the title compound (55.0 mg, 18%) (using H-Ala-NH₂ HCl instead of aminoacetonitrile HCl) which was obtained as a light yellow solid. MS m/e = 379.2 (M+H⁺).

Example 26

(R)-2-[1-Oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide

25 As described for example 16d, 4-(4-trifluoromethyl-benzyloxy)-benzene-1,2-dicarbaldehyde (250 mg, 0.81 mmol) was converted to the title compound (46.9 mg, 15%) (using H-D-Ala-NH₂ HCl instead of aminoacetonitrile HCl) which was obtained as a light yellow solid. MS m/e = 379.3 (M+H⁺).

Example 27

[1-Oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester

As described for example 16d, 4-(4-trifluoromethyl-benzyloxy)-benzene-1,2-dicarbaldehyde (250 mg, 0.81 mmol) was converted to the title compound (32.6 mg, 11%) (using H-D-Ala-NH₂ HCl instead of aminoacetonitrile HCl) which was obtained as a light yellow solid. MS m/e = 380.2 (M+H⁺).

Example 28

2-(2-Methoxy-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one

As described for example 3d, 4-(4-trifluoromethyl-benzyloxy)-benzene-1,2-dicarbaldehyde (250 mg, 0.81 mmol) was converted to the title compound (46.5 mg, 16%) (using 2-methoxyethylamine instead of H-Ala-NH₂ HCl) which was obtained as a white solid. MS m/e = 366.2 (M+H⁺).

Example 29

[1-Oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetonitrile

As described for example 3d, 4-(4-trifluoromethyl-benzyloxy)-benzene-1,2-dicarbaldehyde (250 mg, 0.81 mmol) was converted to the title compound (79.6 mg, 28%) (using aminoacetonitrile HCl instead of H-Ala-NH₂ HCl) which was obtained as a white solid. MS m/e = 346.1 (M⁺).

Example 30

2-(2-Amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride

a) {2-[1-Oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-ethyl}-carbamic acid tert-butyl ester

As described for example 24b, 4-(4-trifluoromethyl-benzyloxy)-benzene-1,2-dicarbaldehyde (250 mg, 0.81 mmol) was converted to the title compound (167.7 mg, 38%) which was obtained as a white solid. MS m/e = 451.3 (M+H⁺).

b) 2-(2-Amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride

As described for example 24b, {2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-ethyl}-carbamic acid tert-butyl ester (160.0 mg, 0.36 mmol) was converted
5 to the title compound (93.6 mg, 68%) which was obtained as a light yellow solid. MS m/e = 351.2 (M+H⁺).

Example A

Tablets of the following composition are produced in a conventional manner:

	<u>mg/Tablet</u>
Active ingredient	100
5 Powdered lactose	95
White corn starch	35
Polyvinylpyrrolidone	8
Na carboxymethylstarch	10
Magnesium stearate	2
10 Tablet weight	<u>250</u>

Example B

Tablets of the following composition are produced in a conventional manner:

	<u>mg/Tablet</u>
Active ingredient	200
15 Powdered lactose	100
White corn starch	64
Polyvinylpyrrolidone	12
Na carboxymethylstarch	20
Magnesium stearate	4
20 Tablet weight	<u>400</u>

Example C

Capsules of the following composition are produced:

	<u>mg/Capsule</u>
Active ingredient	50
5 Crystalline lactose	60
Microcrystalline cellulose	34
Talc	5
Magnesium stearate	1
Capsule fill weight	<u>150</u>

- 10 The active ingredient having a suitable particle size, the crystalline lactose and the microcrystalline cellulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed. The final mixture is filled into hard gelatine capsules of suitable size.


Example D

- 15 An injection solution may have the following composition and is manufactured in usual manner:

	Active substance	1.0 mg
	1 N HCl	20.0 µl
	acetic acid	0.5 mg
20	NaCl	8.0 mg
	phenol	10.0 mg
	1 N NaOH	q.s. ad pH 5
	H ₂ O	q.s. ad 1 ml

Claims

1. Compounds of the general formula




wherein

- | | | |
|----|-----------------------------------|--|
| 5 | X | is $-N=$ or $-CH=$; |
| | R ¹ | is $-(CH_2)_n-CO-NR^5R^6$;
$-(CH_2)_n-NR^5R^6$;
$-(CH_2)_n-COOR^7$;
$-(CH_2)_n-CN$; |
| 10 | | $-(CH_2)_n$ -isoindole-1,3-dionyl; or
$-(CH_2)_p-OR^8$; |
| | R ² | is hydrogen or C ₁ -C ₆ -alkyl; |
| | R ³ | is hydrogen or C ₁ -C ₆ -alkyl; |
| | R ⁴ | is halogen, halogen-(C ₁ -C ₆)-alkyl, C ₁ -C ₆ -alkoxy or |
| 15 | | halogen-(C ₁ -C ₆)-alkoxy; |
| | R ⁵ and R ⁶ | are independently from each other hydrogen or C ₁ -C ₃ -alkyl; |
| | R ⁷ | is C ₁ -C ₆ -alkyl; |
| | R ⁸ | is hydrogen or C ₁ -C ₆ -alkyl; |
| | m | is 1, 2 or 3; |
| 20 | n | is 0, 1 or 2; and |
| | p | is 1 or 2; |

as well as their pharmaceutically acceptable salts.

2. Compounds of formula I or II according to claim 1, wherein X is $-\text{CH}=\text{}$.

3. Compounds of formula I according to claim 1,



wherein

- X is -N= or -CH=;
- 5 R^1 is $-(CH_2)_n-CO-NR^5R^6$;
 $-(CH_2)_n-NR^5R^6$;
 $-(CH_2)_n-COOR^7$;
 $-(CH_2)_n-CN$;
 $-(CH_2)_n$ -isoindole-1,3-dionyl; or
10 $-(CH_2)_p-OR^8$;
- R^2 is hydrogen or C_1-C_6 -alkyl;
- R^3 is hydrogen or C_1-C_6 -alkyl;
- R^4 is halogen, halogen- (C_1-C_6) -alkyl, C_1-C_6 -alkoxy or
halogen- (C_1-C_6) -alkoxy;
- 15 R^5 and R^6 are independently from each other hydrogen or C_1-C_3 -alkyl;
- R^7 is C_1-C_6 -alkyl;
- R^8 is hydrogen or C_1-C_6 -alkyl;
- m is 1, 2 or 3;
- n is 0, 1 or 2; and
- 20 p is 1 or 2;

as well as their pharmaceutically acceptable salts.

4. Compounds of formula I according to claim 3, wherein R^1 is $-(CH_2)_n-CO-NR^5R^6$, and wherein R^5 and R^6 are independently from each other hydrogen or C_1-C_6 -alkyl and n is 0, 1 or 2.


- 25 5. Compounds of formula I according to claim 4, which compounds are selected from the group consisting of
2-[5-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide,
2-[5-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,

(S)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
(R)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
2-[5-(4-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide, and
2-[1-oxo-5-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetamide.

5 6. Compounds of formula I according to claim 3, wherein R^1 is $-(CH_2)_p-OR^8$, and wherein R^8 is C_1-C_6 -alkyl and n is 0, 1, or 2.

7. A compound of formula I according to claim 6, which compound is 5-(3-fluoro-benzyloxy)-2-(2-methoxy-ethyl)-2,3-dihydro-isoindol-1-one.

8. Compounds of formula II according to claim 1,



II

wherein

X is $-N=$ or $-CH=$;

R^1 is $-(CH_2)_n-CO-NR^5R^6$;
 $-(CH_2)_n-NR^5R^6$;
15 $-(CH_2)_n-COOR^7$;
 $-(CH_2)_n-CN$;
 $-(CH_2)_n$ -isoindole-1,3-dionyl; or
 $-(CH_2)_p-OR^8$;

R^2 is hydrogen or C_1-C_6 -alkyl;

20 R^3 is hydrogen or C_1-C_6 -alkyl;

R^4 is halogen, halogen- (C_1-C_6) -alkyl, C_1-C_6 -alkoxy or
halogen- (C_1-C_6) -alkoxy;

R^5 and R^6 are independently from each other hydrogen or C_1-C_3 -alkyl;

R^7 is C_1-C_6 -alkyl;

25 R^8 is hydrogen or C_1-C_6 -alkyl;

m is 1, 2 or 3;

n is 0, 1 or 2; and

p is 1 or 2;

as well as their pharmaceutically acceptable salts.

9. Compounds of formula II according to claim 8, wherein R^1 is $-(CH_2)_n-CO-NR^5R^6$, and wherein R^5 and R^6 are independently from each other hydrogen or C_1-C_6 -alkyl and n is 0, 1 or 2.

- 5 10. Compounds of formula II according to claim 9, which compounds are selected from the group consisting of
2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetamide,
(R)-2-[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-propionamide,
(S)-2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide,
10 and
(R)-2-[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-propionamide.

11. Compounds of formula II according to claim 8, wherein R^1 is $-(CH_2)_n-COOR^7$, and wherein R^7 is C_1-C_6 -alkyl and n is 0, 1, or 2.

12. Compounds of formula II according to claim 11, which compounds are selected
15 from the group consisting of
[6-(3-fluoro-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester, and
[1-oxo-6-(4-trifluoromethyl-benzyloxy)-1,3-dihydro-isoindol-2-yl]-acetic acid methyl ester.

13. Compounds of formula II according to claim 8, wherein R^1 is $-(CH_2)_p-OR^8$, and
20 wherein R^8 is C_1-C_6 -alkyl and p is 1 or 2.

14. Compounds of formula II according to claim 13, which compounds are selected from the group consisting of
2-(2-methoxy-ethyl)-6-(3-fluoro-benzyloxy)-2,3-dihydro-isoindol-1-one, and
2-(2-methoxy-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one.


- 25 15. Compounds of formula II according to claim 8, wherein R^1 is $-(CH_2)_n-NR^5R^6$, and wherein R^5 and R^6 are independently from each other hydrogen or C_1-C_6 -alkyl and n is 0, 1 or 2.

16. Compounds of formula II according to claim 9, which compounds are selected from the group consisting of
30 2-(2-amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride, and
2-(2-amino-ethyl)-6-(4-trifluoromethyl-benzyloxy)-2,3-dihydro-isoindol-1-one 1:1 hydrochloride.

17. Compounds of formula I or II according to claims 1 or 3 or 8, wherein R^4 is
35 halogen or halogen- (C_1-C_6) -alkyl.


18. A process for the manufacture of compounds of formula I or II according to claim 1 as well as their pharmaceutically acceptable salts, which process comprises

a) reacting a compound of formula




III

5 with a compound of formula



IV


to obtain a compound of formula



I

and, if desired, converting a compound of formula I into a pharmaceutically
10 acceptable salt, or

b) by reacting a compound of formula




V

with a compound of formula



IV


to obtain a compound of formula



II


- 5 and, if desired, converting a compound of formula II into a pharmaceutically acceptable salt, or

c) by reacting a compound of formula



VI


which is then treated with a compound of formula



VII

10

to obtain a compound of formula



IIa

and, if desired, converting a compound of formula IIa into a pharmaceutically acceptable salt.

19. A compound of formula I or II according to claim 1, when manufactured by a process according to claim 18.

5 20. A medicament containing one or more compounds as claimed in any one of claims 1 to 17 and pharmaceutically acceptable excipients for the treatment and prevention of diseases which are mediated by monoamine oxidase B inhibitors.

21. The medicament according to claim 20 for the treatment and prevention of Alzheimer's disease and senile dementia.

10 22. A compound of formula I or II according to claim 1 as well as its pharmaceutically acceptable salts for the treatment or prevention of diseases.

23. The use of a compound of formula I or II according to claim 1 as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and prevention of diseases which are mediated by monoamine oxidase B inhibitors.

15 24. The use according to claim 23, wherein the disease is Alzheimer's disease or senile dementia.

25. The invention as herein before described.

THIS PAGE BLANK (USPTO)